Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. This biopharmaceutical company is expected to post quarterly loss of $1.02 per share in its upcoming report, which represents a year-over-year change of +23.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial ...